Cosmo Bio Co

Cosmo Bio Co R&D Expenses

The Research & Development Expenses of Cosmo Bio Co (3386.T) as of Oct 29, 2026 is 83.00 M JPY. In the previous year, Research & Development Expenses was 73.00 M JPY — a change of 13.70% (higher).

R&D Expenses

83.00 MJPY

YoY

13.70%

Last updated:

Research & Development Expenses of Cosmo Bio Co is 2024 83.00 M JPY. Research & Development Expenses of Cosmo Bio Co was 2023 73.00 M JPY. It decreases by 13.70% higher compared to the previous year.

The Cosmo Bio Co R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2016
43.00 M JPY
Jan 1, 2017
96.00 M JPY
Jan 1, 2019
81.00 M JPY
Jan 1, 2020
80.00 M JPY
Jan 1, 2021
70.00 M JPY
Jan 1, 2022
82.00 M JPY
Jan 1, 2023
73.00 M JPY
Jan 1, 2024
83.00 M JPY
The Cosmo Bio Co R&D Expenses history
YEARR&D ExpensesYoY
83.00 MJPY+13.70%
73.00 MJPY-10.98%
82.00 MJPY+17.14%
70.00 MJPY-12.50%
80.00 MJPY-1.23%
81.00 MJPY-15.63%
96.00 MJPY+123.26%
43.00 MJPY-2.27%
44.00 MJPY+12.82%
39.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Research & Development Expenses of Cosmo Bio Co is 83.00 M JPY in 2024.

Research & Development Expenses of Cosmo Bio Co changed from 73.00 M JPY to 83.00 M JPY, representing a 13.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co